Search: onr:"swepub:oai:DiVA.org:uu-343029" >
Treatment of essent...
-
Birgegård, Gunnar,1944-Uppsala universitet,Hematologi
(author)
Treatment of essential thrombocythemia in Europe : a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
- Article/chapterEnglish2018
Publisher, publication year, extent ...
-
2017-10-27
-
Ferrata Storti Foundation,2018
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-343029
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-343029URI
-
https://doi.org/10.3324/haematol.2017.174672DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Evaluation of Anagrelide (Xagrid (R)) Efficacy and Long-term Safety, a phase IV, prospective, non-interventional study performed in 13 European countries enrolled high-risk essential thrombocythemia patients treated with cytoreductive therapy. The primary objectives were safety and pregnancy outcomes. Of 3721 registered patients, 3649 received cytoreductive therapy. At registration, 3611 were receiving: anagrelide (Xagrid (R)) (n=804), other cytoreductive therapy (n=2666), or anagrelide + other cytoreductive therapy (n=141). The median age was 56 vs. 70 years for anagrelide vs. other cytoreductive therapy. Event rates (patients with events/100 patient-years) were 1.62 vs. 2.06 for total thrombosis and 0.15 vs. 0.53 for venous thrombosis. Anagrelide was more commonly associated with hemorrhage (0.89 vs. 0.43), especially with anti-aggregatory therapy (1.35 vs. 0.33) and myelofibrosis (1.04 vs. 0.30). Other cytoreductive therapies were more associated with acute leukemia (0.28 vs. 0.07) and other malignancies (1.29 vs. 0.44). Post hoc multivariate analyses identified increased risk for thrombosis with prior thrombohemorrhagic events, age >= 65, cardiovascular risk factors, or hypertension. Risk factors for transformation were prior thrombohemorrhagic events, age >= 65, time since diagnosis, and platelet count increase. Safety analysis reflected published data, and no new safety concerns for anagrelide were found. Live births occurred in 41/54 pregnancies (76%).
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Besses, Carlos
(author)
-
Griesshammer, Martin
(author)
-
Gugliotta, Luigi
(author)
-
Harrison, Claire N
(author)
-
Hamdani, Mohamed
(author)
-
Wu, Jingyang
(author)
-
Achenbach, Heinrich
(author)
-
Kiladjian, Jean-Jacques
(author)
-
Uppsala universitetHematologi
(creator_code:org_t)
Related titles
-
In:Haematologica: Ferrata Storti Foundation103:1, s. 51-600390-60781592-8721
Internet link
Find in a library
To the university's database